Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling

EMBO Journal

Volumn 31, Issue 11, 2012, Pages 2629-2647

  Röring, Michael ^a   Herr, Ricarda ^a   Fiala, Gina J ^a,b   Heilmann, Katharina ^a   Braun, Sandra ^a   Eisenhardt, Anja E ^a   Halbach, Sebastian ^a   Capper, David ^c,d   Von Deimling, Andreas ^c,d   Schamel, Wolfgang W ^a,b   Saunders, Darren N ^e   Brummer, Tilman ^a,f  

^a UNIVERSITY OF FREIBURG   (Germany)

^b MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e UNIVERSITY OF NEW SOUTH WALES   (Australia)

^f UNIVERSITY OF FREIBURG   (Germany)

Author keywords

A Raf; BRAF; PLX 4032 4720; sorafenib; V600E specific antibody

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; ONCOPROTEIN; RAF PROTEIN; SORAFENIB;

ARTICLE; CONTROLLED STUDY; DIMERIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INACTIVATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN;

BENZENESULFONATES; CACO-2 CELLS; HCT116 CELLS; HT29 CELLS; HUMANS; INDOLES; MAP KINASE SIGNALING SYSTEM; PROTEIN KINASE INHIBITORS; PROTEIN MULTIMERIZATION; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; SULFONAMIDES;

EID: 84861885576     PISSN: 02614189     EISSN: 14602075     Source Type: Journal    
DOI: 10.1038/emboj.2012.100     Document Type: Article

References (92)

1. Abraham D, Podar K, Pacher M, Kubicek M, Welzel N, Hemmings BA, Dilworth SM, Mischak H, Kolch W, Baccarini M (2000) Raf-1-associated protein phosphatase 2A as a positive regulator of kinase activation. J Biol Chem 275: 22300-22304 (Pubitemid 30621814)
2. Albritton LM, Tseng L, Scadden D, Cunningham JM (1989) A putative murine ecotropic retrovirus receptor gene encodes a multiple membrane-spanning protein and confers susceptibility to virus infection. Cell 57: 659-666 (Pubitemid 19140646)
3. Arnault JP, Mateus C, Escudier B, Tomasic G, Wechsler J, Hollville E, Soria JC, Malka D, Sarasin A, Larcher M, Andre J, Kamsu-Kom N, Boussemart L, Lacroix L, Spatz A, Eggermont AM, Druillennec S, Vagner S, Eychene A, Dumaz N et al (2012) Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1. Clin Cancer Res 18: 263-272
4. Baljuls A, Mahr R, Schwarzenau I, Muller T, Polzien L, Hekman M, Rapp UR (2011) Single substitution within the RKTR motif impairs kinase activity but promotes dimerization of RAF kinase. J Biol Chem 286: 16491-16503
5. Birtwistle MR, Kolch W (2011) Biology using engineering tools: the negative feedback amplifier. Cell Cycle 10: 2069-2076
6. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, Burton EA, Wong B, Tsang G, West BL, Powell B, Shellooe R,Marimuthu A, Nguyen H, Zhang KY, Artis DR et al (2010) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467: 596-599
7. Brady SC, Coleman ML, Munro J, Feller SM, Morrice NA, Olson MF (2009) Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation. Cancer Res 69: 6773-6781
8. Brennan DF, Dar AC, Hertz NT, Chao WC, Burlingame AL, Shokat KM, Barford D (2011) A Raf-induced allosteric transition of KSR stimulates phosphorylation of MEK. Nature 472: 366-369
9. Brummer T, Martin P, Herzog S, Misawa Y, Daly R, Reth M (2006) Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein. Oncogene 25: 6262-6276 (Pubitemid 44564743)
10. Brummer T, Naegele H, Reth M, Misawa Y (2003) Identification of novel ERK-mediated feedback phosphorylation sites at the C-terminus of B-Raf. Oncogene 22: 8823-8834 (Pubitemid 38021498)
11. Brummer T, Shaw P, Reth M, Misawa Y (2002) Inducible gene deletion reveals different roles for B-Raf and Raf-1 in B-cell antigen receptor signalling. EMBO J 21: 5611-5622 (Pubitemid 35315261)
12. Camacho-Carvajal MM, Wollscheid B, Aebersold R, Steimle V, Schamel WW (2004) Two-dimensional Blue native/SDS gel electrophoresis of multi-protein complexes from whole cellular lysates: a proteomics approach. Mol Cell Proteomics 3: 176-182 (Pubitemid 38714275)
13. Capon DJ, Seeburg PH, McGrath JP, Hayflick JS, Edman U, Levinson AD, Goeddel DV (1983) Activation of Ki-ras2 gene in human colon and lung carcinomas by two different point mutations. Nature 304: 507-513 (Pubitemid 13026946)
14. Capper D, Preusser M, Habel A, Sahm F, Ackermann U, Schindler G, Pusch S, Mechtersheimer G, Zentgraf H, von Deimling A (2011) Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol 122: 11-19
15. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516
16. Chen AP, Ohno M, Giese KP, Kuhn R, Chen RL, Silva AJ (2006) Forebrain-specific knockout of B-raf kinase leads to deficits in hippocampal long-term potentiation, learning, and memory J Neurosci Res 83: 28-38 (Pubitemid 43062007)
17. Chong H, Lee J, Guan KL (2001) Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J 20: 3716-3727 (Pubitemid 32691783)
18. Cichowski K, Janne PA (2010) Drug discovery: inhibitors that activate. Nature 464: 358-359
19. Claperon A, Therrien M (2007) KSR and CNK: two scaffolds regulating RAS-mediated RAF activation. Oncogene 26: 3143-3158 (Pubitemid 46763011)
20. Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3: ra84
21. Cox AD, Der CJ (2010) The raf inhibitor paradox: unexpected consequences of targeted drugs. Cancer Cell 17: 221-223
22. Dajee M, Tarutani M, Deng H, Cai T, Khavari PA (2002) Epidermal Ras blockade demonstrates spatially localized Ras promotion of proliferation and inhibition of differentiation. Oncogene 21: 1527-1538 (Pubitemid 34226140)
23. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes S, Hughes J, Kosmidou V, Menzies A et al (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949-954 (Pubitemid 34716871)
24. Dhillon AS, Meikle S, Yazici Z, Eulitz M, Kolch W (2002) Regulation of Raf-1 activation and signalling by dephosphorylation. EMBO J 21: 64-71 (Pubitemid 34087075)
25. Downward J (2011) Targeting RAF: trials and tribulations. Nat Med 17: 286-288
26. Eisenhardt AE, Olbrich H, Röring M, Janzarik W, Anh TN, Cin H, Remke M, Witt H, Korshunov A, Pfister SM, Omran H, Brummer T (2011) Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma. Int J Cancer 129: 2297-2303
27. Emuss V, Garnett M, Mason C, Marais R (2005) Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF. Cancer Res 65: 9719-9726 (Pubitemid 41541448)
28. Evan GI, Lewis GK, Ramsay G, Bishop JM (1985) Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. Mol Cell Biol 5: 3610-3616 (Pubitemid 16233068)
29. Fischer A, Baljuls A, Reinders J, Nekhoroshkova E, Sibilski C, Metz R, Albert S, Rajalingam K, Hekman M, Rapp UR (2009) Regulation of RAF activity by 14-3-3 proteins: RAF kinases associate functionally with both homo- and heterodimeric forms of 14-3-3 proteins. J Biol Chem 284: 3183-3194
30. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, Brummer T, Sers C, Bluthgen N (2011) Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Mol Syst Biol 7: 489
31. Garnett MJ, Marais R (2004) Guilty as charged: B-RAF is a human oncogene. Cancer Cell 6: 313-319 (Pubitemid 39361432)
32. Garnett MJ, Rana S, Paterson H, Barford D, Marais R (2005) Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol Cell 20: 963-969 (Pubitemid 41814884)
33. Gauchotte G, Philippe C, Lacomme S, Leotard B, Wissler MP, Allou L, Toussaint B, Klein M, Vignaud JM, Bressenot A (2011) BRAF, p53 and SOX2 in anaplastic thyroid carcinoma: evidence for multistep carcinogenesis. Pathology 43: 447-452
34. Guan K, Figueroa C, Brtva T, Zhu T, Taylor J, Barber T, Vojtek A (2000) Negative regulation of the serine/threonine kinase B-Raf by Akt. J Biol Chem 275: 27354-27359
35. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, Ludlam MJ, Stokoe D, Gloor SL, Vigers G, Morales T, Aliagas I, Liu B, Sideris S, Hoeflich KP, Jaiswal BS, Seshagiri S, Koeppen H, Belvin M, Friedman LS et al (2010) RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464: 431-435
36. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R (2010) Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140: 209-221
37. Herr R, Wöhrle FU, Danke C, Berens C, Brummer T (2011) A novel MCF-10A line allowing conditional oncogene expression in 3D culture. Cell Commun Signal 9: 17
38. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA (2003) Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res 63: 5198-5202 (Pubitemid 37139827)
39. Houben R, Voigt H, Noelke C, Hofmeister V, Becker JC, Schrama D (2009) MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib. Mol Cancer Ther 8: 433-440
40. Huber S, Oelsner M, Decker T, zum Buschenfelde CM, Wagner M, Lutzny G, Kuhnt T, Schmidt B, Oostendorp RA, Peschel C, Ringshausen I (2011) Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 25: 838-847
41. Jaffe AB, Kaji N, Durgan J, Hall A (2008) Cdc42 controls spindle orientation to position the apical surface during epithelial morphogenesis. J Cell Biol 183: 625-633
42. Jaumot M, Hancock JF (2001) Protein phosphatases 1 and 2A promote Raf-1 activation by regulating 14-3-3 interactions. Oncogene 20: 3949-3958 (Pubitemid 32681600)
43. Jones DT, Kocialkowski S, Liu L, Pearson DM, Ichimura K, Collins VP (2009) Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene 28: 2119-2123
44. Kamata T, Pritchard C (2011) Mechanisms of aneuploidy induction by RAS and RAF oncogenes. Am J Cancer Res 1: 955-971
45. Kaplan FM, Shao Y, Mayberry MM, Aplin AE (2011) Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 30: 366-371
46. Karreth FA, DeNicola GM, Winter SP, Tuveson DA (2009) C-Raf inhibits MAPK activation and transformation by B-Raf(V600E). Mol Cell 36: 477-486
47. Kubo T, Kuroda Y, Kokubu A, Hosoda F, Arai Y, Hiraoka N, Hirohashi S, Shibata T (2009) Resequencing analysis of the human tyrosine kinase gene family in pancreatic cancer. Pancreas 38: e200-e206
48. Lavoie H, Therrien M (2011) Cancer: A drug-resistant duo. Nature 480: 329-330
49. Leevers SJ, Paterson HF, Marshall CJ (1994) Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane. Nature 369: 411-414 (Pubitemid 24184056)
50. Light Y, Paterson H, Marais R (2002) 14-3-3 antagonizes ras-mediated raf-1 recruitment to the plasma membrane to maintain signaling fidelity. Mol Cell Biol 22: 4984-4996 (Pubitemid 34700691)
51. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 4: ra17
52. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, Hughes TM, Thompson JF, Scolyer RA, Kefford RF (2011) Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 29: 1239-1246
53. MacNicol MC, Muslin AJ, MacNicol AM (2000) Disruption of the 14-3-3 binding site within the B-Raf kinase domain uncouples catalytic activity from PC12 cell differentiation. J Biol Chem 275: 3803-3809 (Pubitemid 30094602)
54. Marais R, Light Y, Paterson HF, Mason CS, Marshall CJ (1997) Differential regulation of Raf-1, A-Raf, and B-Raf by oncogenic ras and tyrosine kinases. J Biol Chem 272: 4378-4383 (Pubitemid 27078513)
55. Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R (1999) Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation. EMBO J 18: 2137-2148 (Pubitemid 29179171)
56. Matallanas D, Birtwistle M, Romano D, Zebisch A, Rauch J, von Kriegsheim A, Kolch W (2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2: 232-260
57. Matos P, Oliveira C, Velho S, Goncalves V, da Costa LT, Moyer MP, Seruca R, Jordan P (2008) B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 135: 899-906
58. McKay MM, Ritt DA, Morrison DK (2011) RAF inhibitor-induced KSR1/B-RAF binding and its effects on ERK cascade signaling. Curr Biol 21: 563-568
59. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS (2008) BRAF(E600) in benign and malignant human tumours. Oncogene 27: 877-895 (Pubitemid 351225383)
60. Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977
61. Niihori T, Aoki Y, Narumi Y, Neri G, Cave H, Verloes A, Okamoto N, Hennekam RC, Gillessen-Kaesbach G, Wieczorek D, Kavamura MI, Kurosawa K, Ohashi H, Wilson L, Heron D, Bonneau D, Corona G, Kaname T, Naritomi K, Baumann C et al (2006) Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 38: 294-296
62. Noble C, Mercer K, Hussain J, Carragher L, Giblett S, Hayward R, Patterson C, Marais R, Pritchard CA (2008) CRAF autophosphorylation of serine 621 is required to prevent its proteasomemediated degradation. Mol Cell 31: 862-872
63. Oikonomou E, Makrodouli E, Evagelidou M, Joyce T, Probert L, Pintzas A (2009) BRAF(V600E) efficient transformation and induction of microsatellite instability versus KRAS(G12V) induction of senescence markers in human colon cancer cells. Neoplasia 11: 1116-1131
64. Old WM, Shabb JB, Houel S, Wang H, Couts KL, Yen CY, Litman ES, Croy CH, Meyer-Arendt K, Miranda JG, Brown RA, Witze ES, Schweppe RE, Resing KA, Ahn NG (2009) Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma. Mol Cell 34: 115-131
65. Papin C, Denouel-Galy A, Laugier D, Calothy G, Eychene A (1998) Modulation of kinase activity and oncogenic properties by alternative splicing reveals a novel regulatory mechanism for B-Raf. J Biol Chem 273: 24939-24947 (Pubitemid 28455002)
66. Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG et al (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480: 387-390
67. Poulikakos PI, Rosen N (2011) Mutant BRAF melanomas-dependence and resistance. Cancer Cell 19: 11-15
68. Poulikakos PI, Solit DB (2011) Resistance to MEK inhibitors: should we co-target upstream? Sci Signal4 pe16
69. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N (2010) RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464: 427-430
70. Rajakulendran T, Sahmi M, Lefrancois M, Sicheri F, Therrien M (2009) A dimerization-dependent mechanism drives RAF catalytic activation. Nature 461: 542-545
71. Ribas A, Flaherty KT (2011) BRAF targeted therapy changes the treatment paradigm in melanoma. Nat Rev Clin Oncol 8: 426-433
72. Ritt DA, Monson DM, Specht SI, Morrison DK (2010) Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling. Mol Cell Biol 30: 806-819
73. Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F (2006b) A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Mol Cell 22: 217-230
74. Rodriguez-Viciana P, Tetsu O, Tidyman WE, Estep AL, Conger BA, Cruz MS, McCormick F, Rauen KA (2006a) Germline mutations in genes within the MAPK pathway cause cardio-facio-cutaneous syndrome. Science 311: 1287-1290 (Pubitemid 43334718)
75. Rushworth L, Hindley A, O'Neill E, Kolch W (2006) Regulation and role of Raf-1/B-Raf heterodimerization. Mol Cell Biol 26: 2262-2272 (Pubitemid 43346926)
76. Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, Petrangeli V, Dentici ML, Mancini GM, Selicorni A, Rossi C, Mazzanti L, Marino B, Ferrero GB, Silengo MC, Memo L et al (2009) Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 30: 695-702
77. Schilling M, Maiwald T, Hengl S, Winter D, Kreutz C, Kolch W, Lehmann WD, Timmer J, Klingmuller U (2009) Theoretical and experimental analysis links isoform-specific ERK signalling to cell fate decisions. Mol Syst Biol 5: 334
78. Schindler G, Capper D, Meyer J, Janzarik W, Omran H, Herold-Mende C, Schmieder K, Wesseling P, Mawrin C, Hasselblatt M, Louis DN, Korshunov A, Pfister S, Hartmann C, Paulus W, Reifenberger G, von Deimling A (2011) Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 121: 397-405
79. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T (1993) Altered growth of human colon cancer cell lines disrupted at activated Kiras. Science 260: 85-88 (Pubitemid 23122749)
80. Solit D, Sawyers CL (2010) How melanomas bypass new therapy. Nature 468: 902-903
81. Solit DB, Rosen N (2011) Resistance to BRAF inhibition in melanomas. N Engl J Med 364: 772-774
82. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M, Faghih M, Brendel E, Voliotis D, Haase CG, Schwartz B, Awada A, Voigtmann R, Scheulen ME, Seeber S (2005) Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol 23: 965-972 (Pubitemid 46202316)
83. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M et al (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366: 207-215
84. Terai K, Matsuda M (2006) The amino-terminal B-Raf-specific region mediates calcium-dependent homo- and hetero-dimerization of Raf. EMBO J 25: 3556-3564 (Pubitemid 44264866)
85. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, Sproesser K, Li L, Smalley KS, Fong D, Zhu YL, Marimuthu A, Nguyen H, Lam B, Liu J, Cheung I et al (2008) Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 105: 3041-3046 (Pubitemid 351723664)
86. Walther A, Johnstone E, Swanton C, Midgley R, Tomlinson I, Kerr D (2009) Genetic prognostic and predictive markers in colorectal cancer. Nat Rev Cancer 9: 489-499
87. Wan P, Garnett M, Roe S, Lee S, Niculescu-Duvaz D, Good V, Jones C, Marshall C, Springer C, Barford D, Marais R (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 116: 855
88. Weber CK, Slupsky JR, Kalmes HA, Rapp UR (2001) Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res 61: 3595-3598 (Pubitemid 32694968)
89. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I et al (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64: 7099-7109 (Pubitemid 39331023)
90. Wimmer R, Baccarini M (2010) Partner exchange: protein-protein interactions in the Raf pathway. Trends Biochem Sci 35: 660-668
91. Yu J, Deshmukh H, Gutmann RJ, Emnett RJ, Rodriguez FJ, Watson MA, Nagarajan R, Gutmann DH (2009) Alterations of BRAF and HIPK2 loci predominate in sporadic pilocytic astrocytoma. Neurology 73: 1526-1531
92. Zhang BH, Guan KL (2000) Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J 19: 5429-5439